Phaseline

Targets › TK2

TK2 (Thymidine kinase 2, mitochondrial): drug programs, companies and trials

3 programs from 3 companies in 4 trials: 2 Phase 2, 2 Phase 1; Neurology; next expected readout Dec 2026.

Phosphorylates thymidine, deoxycytidine, and deoxyuridine in the mitochondrial matrix. In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on TK2 and DGUOK. Widely used as target of antiviral and chemotherapeutic agents. (UniProt, O00142)

Open in Phaseline: the race on TK2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Cristina Domínguez GonzálezDoxecitine and Doxribtimine
Nucleoside analogues for mitochondrial DNA synthesis in TK2 deficiency
TK2Phase 2Thymidine Kinase 2 (TK2 ) DeficiencyJan 2027
Kenneth Myers, MDdeoxycytidine and deoxythymidine (dC/dT)
Nucleotide replacement therapy; supplies deoxycytidine and deoxythymidine to restore mitoc
TK2, DTYMKPhase 2Mitochondrial DiseasesJun 2029
Columbia UniversityThymidine
Mitochondrial DNA nucleotide precursor; substrate for TK2-mediated conversion to deoxythym
TK2Phase 1Mitochondrial DNA Depletion Syndrome 2 Myopathic TypeDec 2026

Conditions

Mitochondrial DNA Depletion Syndrome 2 Myopathic Type (2) Mitochondrial Diseases (1) Thymidine Kinase 2 (TK2 ) Deficiency (1)

Modalities

small molecule (3)

Companies

Kenneth Myers, MD (1) Columbia University (1) Cristina Domínguez González (1)

Related targets

DTYMK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.